<DOC>
	<DOCNO>NCT02743572</DOCNO>
	<brief_summary>The purpose study determine whether iron-fortified PN effective preventative treatment preterm infant . Preterm infant risk anemia especially preterm infant . Anemia effect grow development , clinical prognosis , cognition , movement , learn ability behavioral development . As enteral nutrition feasible soon birth preterm infant , parenteral iron administration efficacious method investigator select . For preterm infant , use parenteral nutrition ( PN ) common first ten day life , investigator hypothesis iron-fortified PN may preventative treatment effect preterm infant use PN supplementation oral nutrition ; Iron-fortified PN also improve iron store status preterm infant . The high concentration iron use study , large preventative treatment effect preterm infant anemia ; safe add small dose iron agent PN .</brief_summary>
	<brief_title>Iron-fortified Parenteral Nutrition Prevention Treatment Anemia Premature Infants</brief_title>
	<detailed_description>Infants risk anemia especially preterm infant . Generally small birth weight gestational age , high anemia ate infant . As enteral nutrition feasible soon birth preterm infant , parenteral iron administration efficacious method investigator select . Meeting Inclusion Criteria study randomly divide five group , control group , group1 ( 100μg/kg/d , high concentration iron ≤0.8g/100ml PN ) , group2（200μg/kg/d , high concentration iron ≤0.8g/100ml PN ) , group3 ( 300μg/kg/d , high concentration iron ≤0.8g/100ml PN ) , group4 ( 400μg/kg/d , high concentration iron ≤0.8g/100ml PN ) . Iron supplementation period ten day . For five group , complete blood count , differential count , reticulocyte count measure weekly sample obtain , serum iron , iron protein , total iron bind force measure baseline 2 week . Through comparative analysis five group , find iron-fortified PN whether affect anemia rate iron storage premature infant . The investigator also select malondialdehyde ( MDA ) 8-isoprostaglandin F2α ( 8-iso-PGF2α ) investigator concern iron use PN induces oxidative stress index . Iron protein determination use radioimmunoassay method , serum iron total iron bind force determination use chemical method , MDA 8-iso-PGF2α determination use enzyme-linked immunosorbent assay method . The investigator hypothesis iron-fortified PN may preventative treatment effect preterm infant use PN supplementation parenteral nutrition ; Iron-fortified PN also improve iron store status preterm infant . The high concentration iron use study , large preventative treatment effect preterm infant anemia .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Preterm infant birth weight less 2kg Have parenteral nutrition indication With write informed consent parent guardian Have already use PN randomization Kidney liver function abnormal Have hemolytic disease Have hemorrhagic disease Have Serious congenital malformation Have septicemia Have plethora newborn Use PN less ten day</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>48 Hours</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>premature infant</keyword>
	<keyword>anemia</keyword>
	<keyword>iron-fortification</keyword>
	<keyword>parenteral nutrition</keyword>
	<keyword>randomize control trial</keyword>
</DOC>